AstraZeneca’s Fasenra meets primary endpoint in MANDARA Phase 3 trial for EGPA
AstraZeneca's Fasenra met its primary endpoint in the MANDARA Phase III trial, offering a monthly treatment option for eosinophilic granulomatosis with polyangiitis (EGPA) patients. Fasenra ... Read More
FDA refuses to approve AstraZeneca’s sBLA for Fasenra in CRSwNP
The US Food and Drug Administration (FDA) has refused to approve the supplemental biologics license application (sBLA) of AstraZeneca’s asthma drug Fasenra (benralizumab) for the ... Read More